case_images: PMC3095904_01
case_images: The results of the pulmonary function tests three months before admission.
case_images: JA2011-479129.001.jpg
case_images: PMC3095904_01_JA2011-479129.001.jpg
case_images: fig1
case_images: Pulmonary function tests, which had been conducted three months before admission, showed a pattern of obstruction (Figure 1). 
case_images: The clinical course. (SFC: fluticasone/salmeterol, LVFX: levofloxacin, and PAPM/BP: panipenem/betamipron.)
case_images: JA2011-479129.002.jpg
case_images: PMC3095904_01_JA2011-479129.002.jpg
case_images: fig2
case_images: Next, 300 mg per day of omalizumab was administered; however, her dyspnea persisted (Figure 2) and her chest radiograph showed atelectasis of the left lung (Figure 3).
case_images: A chest radiograph showed atelectasis of the left lung.
case_images: JA2011-479129.003.jpg
case_images: PMC3095904_01_JA2011-479129.003.jpg
case_images: fig3
case_images: Next, 300 mg per day of omalizumab was administered; however, her dyspnea persisted (Figure 2) and her chest radiograph showed atelectasis of the left lung (Figure 3).
case_images: A chest radiograph showed an improvement in the atelectasis of the left lung.
case_images: JA2011-479129.004.jpg
case_images: PMC3095904_01_JA2011-479129.004.jpg
case_images: fig4
case_images: Her symptoms and respiratory status did not change during the first week, but, thereafter, the atelectasis improved (Figure 4).